Gefitinib (ZD1839)

Name: Gefitinib (ZD1839)
Brand: Selleck Chemicals
SKU: S1025
Rating: 5 (360 reviews)

For research use only.

Catalog No.S1025

360 publications

Molecular Weight(MW): 446.90

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Selleck's Gefitinib (ZD1839) has been cited by 360 publications

Cell Stem Cell, 2020, 7;26(5):782-792e7

PubMed: 32348727 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 21;11(1):1923

PubMed: 32317663 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 6(11):eaax2271

PubMed: 32195335 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )
Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Aging Cell, 2020, 22:e13145

PubMed: 32323422 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Front Immunol, 2020, 10:3135

PubMed: 32082304 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371577 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 31 pii: mcp

PubMed: 32234966 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

J Cancer, 2020, 6;11(13):3762-3770

PubMed: 32328181 ( click the link to review the publication )

Cancer Sci, 2020, 111(5):1652-1662

PubMed: 32133706 ( click the link to review the publication )

Biomolecules, 2020, 10(1)

PubMed: 31947839 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Mol Cancer Res, 2020, 25

PubMed: 32098826 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5578-5592

PubMed: 32248643 ( click the link to review the publication )
J Cell Mol Med, 2020, 24(10):5811-5816

PubMed: 32281297 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

Eur J Pharmacol, 2020, 5;874:172961

PubMed: 32044322 ( click the link to review the publication )

Thorac Cancer, 2020, 5

PubMed: 32368855 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13533

PubMed: 32558328 ( click the link to review the publication )

J Thorac Dis, 2020, 12(3):712-723

PubMed: 32274137 ( click the link to review the publication )

Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):670

PubMed: 32820157 ( click the link to review the publication )

Exp Mol Med, 2020, 10.1038/s12276-020-0474-1

PubMed: 32728068 ( click the link to review the publication )

Cells, 2020, 9(8):E1830

PubMed: 32756527 ( click the link to review the publication )

Cytometry A, 2020, 97(1):70-77

PubMed: 31411813 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Cell Rep, 2020, 32(5):107994

PubMed: 32755586 ( click the link to review the publication )

Exp Cell Res, 2020, 390(2):111950

PubMed: 32188578 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )
Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(14):2464-2481

PubMed: 30532069 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )

Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )
Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )
Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

J Cancer Prev, 2019, 24(4):217-223

PubMed: 31950021 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Exp Ther Med, 2019, 18(5):3793-3800

PubMed: 31611933 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Nat Microbiol, 2019, 4(2):216-225

PubMed: 30420785 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 3;37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

Antiviral Res, 2018, 150:20-29

PubMed: 29224735 ( click the link to review the publication )
Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )
Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Oncogene, 2017, 36(8):1102-1111

PubMed: 27524413 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )
Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )

Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )

Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Sci Rep, 2016, 6:32258

PubMed: 27558531 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )
Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27959-74

PubMed: 27058897 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )
Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 154(2):225-37

PubMed: 26487496 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144368

PubMed: 26656173 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10146-60

PubMed: 25760142 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )
Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

J BUON, 2014, 19(2):466-73

PubMed: 24965408 ( click the link to review the publication )
Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):4765-78

PubMed: 24946858 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

Neuro Oncol, 2013, 15(11):1469-78

PubMed: 24101737 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )
Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnm5TWM2OD1yLkC1OEDPxE1?	MVOxOlUyPjR5Mx?=
NIH3T3	M1[we2Z2dmO2aX;uJGF{e2G7	NVPZ[4NXOC5{IN88US=>	MYCyJIg>	M1v2NGROW09?	NXfCUYhsUW6qaXLpeIlwdiCxZjDFS2Yhe3SrbYXsZZRm\CCqdX3hckBmemKEMTDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCxOFQh\|ryP	NXWzOoR[OTZ2OECyPFQ>
COS7	M2nLXmZ2dmO2aX;uJGF{e2G7	NYHJXlNQQTZizszN			NHz3TZlKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\A>?	MojUNVcyPzh5MkK=
A549	NYHRWHRLS3m2b4TvfIlkKEG\|c3H5		NFn5Vm06PiCq	NIroVFZFVVOR	MmnBTWM2OD1zMz61PUDPxE1?	NWr2bmdYOTh\|MUO4NFc>
K562	NFvPWGZEgXSxdH;4bYMhSXO\|YYm=		NHj6XJk6PiCq	NXTRT\|BRTE2VTx?=	M3;5[WlEPTB;OT6zOkDPxE1?	MWSxPFMyOzhyNx?=
MDA-MB-231	NHmy[Y9EgXSxdH;4bYMhSXO\|YYm=		NXjyOIozQTZiaB?=	NFTufGdFVVOR	NYX3eIRoUUN3ME2zOk43OSEQvF2=	Moe4NVg{OTN6MEe=
MOLT4	MUPDfZRwfG:6aXOgRZN{[Xl?		M363Xlk3KGh?	MlTDSG1UVw>?	MlK5TWM2OD1zNT6wNkDPxE1?	NFnrfG8yQDNzM{iwOy=>
MCF7	M2DqSGN6fG:2b4jpZ{BCe3OjeR?=	MkHROVAh\|ryP	MVO3NkBp		MX;JR\|UxRTF{LkC1JO69VQ>?	M4nFfVE5PzdzOEG5
BT474	M2q3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHnzc3g4OiCq		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKWNEe0JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWUQnKyJJdqfGhiRVO1NEBw\iByLkOg{txO	NFSxSVcyQTB{OESyOC=>
HN5	NWfrelF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYrMZo93PzJiaB?=		NFHwOFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDveoVz\XiycnXzd4lv\yCHR1\SJJdqfGhiRVO1NEBw\iByLkCxJO69VQ>?	M{HETlE6ODJ6NEK0
BA/F3	MonKR5l1d3SxeHnjJGF{e2G7		MX23NkBp		NWO3TIhDS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSJI12fGGwdDD3bZRpKEmFNUCgc4YhOC5yMUC4JO69VQ>?	MmrlNVkzOzl{Mkm=
NIH3T3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX7vXlh7PzJiaB?=		MUPHdo94fGhiaX7obYJqfGmxbjDv[kBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGW6cILld5NqdmdiZYLCNkBo\W6nIIfpeIghUUN3MDDv[kAxNjV2IN88US=>	MWWxPVY3PTN5Nx?=
MCF7 MX	MWLGeY5kfGmxbjDBd5NigQ>?		MU[zNEBucW5?		NGTVUZVKdmirYnn0bY9vKG:oIFLDVnAh\XiycnXzd4VlKHerdHigTWM2OCCxZjCxMlEh\|ryP	MkP4NVk6OzJ7NkC=
A431	NXnLcYh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUC0cmlQOTBizszN	M{\VT\|czKGh?		M1LkZmdKPTB;MD61NVQh\|ryP	NF:wOGoyQTl4OUS2OS=>
A431	NVH4em1tU2mwYYPlJGF{e2G7	MVewMlEh\|ryP	MV:xJIg>		NEnyVXNKdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9v	M4nJeFE6QTZ7NE[1
A431	M2\0VmtqdmG\|ZTDBd5NigQ>?	Mkj6NVAxKM7:TR?=	NFfncGwyOCCvaX6=		MV;Qdo9td26pZXSgbY5pcWKrdH;yfUBi[3Srdnn0fUBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>	M2r0[lE6QTZ7NE[1
Sf9	Ml[yT4lv[XOnIFHzd4F6		MVSxNEBucW5?	Ml7FSG1UVw>?	NUHBTnFrUW6qaXLpeIlwdiCxZjDFS2ZTKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKnY3XweI9zKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN\|IN88US=>	M1zyXVIxODV4NEK1
NCI-H1975	NVXIPW1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYi1JO69VQ>?	NYjzNoJzPzJiaB?=		MV\JR\|UxRThwMk[g{txO	NHf3ZmkzODF3MU[3NC=>
NCI-H1975	MoPMT4lv[XOnIFHzd4F6	MW[xNEDPxE1?			NVHGPVNEUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	NEDMTWgzODF3MU[3NC=>
NCI-H1975	M2nmfGZ2dmO2aX;uJGF{e2G7	NInqNokyOCEQvF2=			NGrEdXhKdmirYnn0bY9vKG:oIFXSRmIzKGG3dH;wbI9{eGixconsZZRqd25?	NH;POZYzODF3MU[3NC=>
NCI-H1975	NH33T2ZHfW6ldHnvckBCe3OjeR?=	MkfCOUDPxE1?	M3\VdVQ5KGh?		M1OyVGlv\HWldHnvckBw\iCjcH;weI9{cXNiYYPz[ZN{\WRiYYOgZYN1cX[jdHnvckBw\iClYYPwZZNmNTN?	MWKyNFE2OTZ5MB?=
A375	NYrLblJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFTieHc1QCCq		NVvve4U{UUN3ME2yNE42PSEQvF2=	NFrGSm0zODNyNEWzOy=>
SMMC7721	NHmwcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGLCflY1QCCq		NHTqem1KSzVyPUOzMlEzKM7:TR?=	M4nzVFIxOzB2NUO3
DU145	NH7mdpFEgXSxdH;4bYMhSXO\|YYm=		MlnKOUBl	MmL5SG1UVw>?	NEjnV2NKSzVyPUSyMlE4KM7:TR?=	MYGyNFQ3PjV3NR?=
MIAPaCa2	NY\iXGpbS3m2b4TvfIlkKEG\|c3H5		NInJWm02KGR?	NYT2VlRPTE2VTx?=	M3nze2lEPTB;NUCuOlIh\|ryP	M{HET\|IxPDZ4NUW1
PANC1	M1;WT2N6fG:2b4jpZ{BCe3OjeR?=		M{DIc\|Uh\A>?	NV\LSWVkTE2VTx?=	NVjEeJlZUUN3ME20NE41OiEQvF2=	MnGxNlA1PjZ3NUW=
PC9	Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\DRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDFS2ZTNWSnZnnjbYVvfCCqdX3hckBRSzliY3XscJMhf2m2aDDFR\|UxKG:oIECuNFE4KM7:TR?=	MU[yNVIxQDhyMh?=
PC9	NVT1W3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTE[VFOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>	MY[yNVIxQDhyMh?=
PC3	M3z1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUGxNEDPxE1?	MX23NkBp	NI\KXpFFVVOR	MkDCTWM2OD15LkSg{txO	MWOyNVM2OzV2Nh?=
MDA-MB-468	M3r6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3HOJdmOTByIN88US=>	NX7LRYVEPDhiaB?=	M1nTeGROW09?	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eR?=	NWP3N5czOjF2Mkm2N\|I>
Plasmodium falciparum					MnHJdWhVWyCycn;mbYxqdmdiZn;yJIlvcGmkaYTvdpMhd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJJBzd2yrZnXyZZRqd25?	NXPodm5iOjF6MUewOFU>
NCI-H1993	NEDK[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4DqUFczKGh?	NHfz[YlFVVOR	MUTJR\|UxRTBwMTFOwG0>	Ml;6NlE6OTZ2M{O=
NCI-H292	NF21RWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXzHbo1sPzJiaB?=	M1\sfmROW09?	M2DoS2lEPTB;MD6wNkDPxE1?	M4XPN\|IyQTF4NEOz
A431	NXjXcVRNU2mwYYPlJGF{e2G7		M1XxXVIhcA>?	M{S3d2ROW09?	NGDERVdKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKEWJRj3zeIlufWyjdHXkJIh2dWGwIFG0N\|Ehf2m2aDDJR\|UxKG:oIECuNFAyKM7:TR?=	MX6yNlExOTF\|Mh?=
MCF7	NYG4SGFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH0NVAxyqEQvHevcWw>	NWq5[IhXPDhiaB?=	M2KxT2ROW09?	Mki0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWJRmKg[4Vv\SC5aYToJGlEPTBib3[gNVIvODVizszN	M17WPFIzOTF7MUOw
BT474	M2XkdGN6fG:2b4jpZ{BCe3OjeR?=	M3joTFExKM7:TR?=	M4\4VlQ5KGh?		MlO5R5l1d3SxeHnjbZR6KGGpYXnud5Qhe2W{dX2td5Rien[nZDDoeY1idiCEVES3OEBk\Wyucx?=	NITKNWkzOjF\|OEOwPC=>
MCF7	NGjQVolEgXSxdH;4bYMhSXO\|YYm=	Ml;BNVAh\|ryP	Mm\zOFghcA>?		M{L6Z2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iTVPGO{Bk\WyuczDveoVzNWW6cILld5NqdmdiRYLiRlIh[2WubIO=	MVeyNlE{QDNyOB?=
HCC827	MYLLbY5ie2ViQYPzZZk>	MUWwMlEzPSEQvF2=	MonmNlQhcA>?	NGLXO5NFVVOR	MYTJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQhYTFyNkigZZV1d3Cqb4PwbI9zgWyjdHnvci=>	MVyyNlM{QTN2Mh?=
HCC827	MWXLbY5ie2ViQYPzZZk>	MYGwMlEzPSEQvF2=	MYGyOEBp	MnnGSG1UVw>?	Mlz5TY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51NW2nZHnheIVlKEW{azDwbI9{eGixconsZZRqd25?	NVPRZpYyOjJ\|M{mzOFI>
HCC827	MV3LbY5ie2ViQYPzZZk>	MV:wMlEzPSEQvF2=	MmniNlQhcA>?	NGjCdW1FVVOR	M1:2SGlvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfC2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w	NWHiU5ZvOjJ\|M{mzOFI>
A431	MkHoT4lv[XOnIFHzd4F6	M17iTVExOCEQvF2=	NGHhNZg{OCCvaX6=		NFPsbHRKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	MmT6NlI3QTh5OEK=
H460	NI\iUoJEgXSxdH;4bYMhSXO\|YYm=		NH:w[WM4OiCq		MXjJR\|UxRTVwNUmg{txO	Mn\uNlI4Ojd2NEm=
HT-29	NGTVd3hEgXSxdH;4bYMhSXO\|YYm=		MnHMO\|IhcA>?		NVHnSmRrUUN3ME2zMlM3KM7:TR?=	NXzMTlBpOjJ5Mke0OFk>
SGC7901	MoW0R5l1d3SxeHnjJGF{e2G7		M3XvfVczKGh?		MnnxTWM2OD1zMD6yOkDPxE1?	NULKXFUxOjJ5Mke0OFk>
A498	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvBUVhySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFk5KGOnbHzzJIV5eHKnc4PpcochTUeIUjDhcoQhW1KFIIfpeIghUUN3MDDv[kA5NjZizszN	M3vzOVIzQDF6OES4
Calu3	NVfy[W1US3m2b4TvfIlkKEG\|c3H5	Mk\0NVAh\|rypL33M	NYXIe5o1PzJiaB?=		M3PQVWlEPTB;MT62JO69VQ>?	NEPVW4kzOzFzNkG2PC=>
FADU	M4LwfGN6fG:2b4jpZ{BCe3OjeR?=	M4PWTFExKM7:Zz;tUC=>	M4TySlczKGh?		MWfJR\|UxRTBwMEWg{txO	M37QXlI{OTF4MU[4
HCC827	NIn6[Y9EgXSxdH;4bYMhSXO\|YYm=	M2\hdVExKM7:Zz;tUC=>	MoDtO\|IhcA>?		NVztfoxTUUN3ME2wMlAxOTVizszN	MWiyN\|EyPjF4OB?=
PC9	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTVNVAh\|rypL33M	Mn65O\|IhcA>?		MmjjTWM2OD1yLkCxOEDPxE1?	NIrG[lMzOzFzNkG2PC=>
Sf9	MmX2T4lv[XOnIFHzd4F6		MXyxJIg>	M{H4OWROW09?	M4eweWlvcGmkaYTpc44hd2ZiaIXtZY4hT1OWLYTh[4dm\CCHR1\SJGw5OzSUIH31eIFvfCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODF3IN88US=>	MnSyNlM3OTF4OUG=
16HBE14o-	M2PHcmN6fG:2b4jpZ{BCe3OjeR?=	MUexNEDPxE1?	MnzWO\|IhcA>?	NFTXV3dFVVOR	MlHlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gNVZJSkVzNH:tJINmdGy\|IHjhdoJwemmwZzD3bYxlKHS7cHWgSWdHWiCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOTJwN{Gg{txO	NGDLTJAzOzZ4OES0NS=>
NCI-H1975	MXPDfZRwfG:6aXOgRZN{[Xl?	NWnG[4JCOTBizszN	MnHRO\|IhcA>?	NWLZWYFLTE2VTx?=	MlHuR5l1d3SxeHnjbZR6KGGpYXnud5Qh\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhPi57MUeg{txO	MY[yN\|Y3QDR2MR?=
16HBE	NUDa[IZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHXkNVY4OiCq	MVHEUXNQ	NG\T[JNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEG2TGJGKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKge4l1cCCLQ{WwJI9nKDFwNkCxJO69VQ>?	Mm\CNlM4QTJ\|MUi=
16HBE	NWj0R5ZGTnWwY4Tpc44hSXO\|YYm=	MWWxNFAh\|ryP	NV6zemRyOTVyIH3pci=>	MX3EUXNQ	Mkf4TY5lfWO2aX;uJI9nKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGi3bXHuJFE3UEKHIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnI>	NUXmWpYxOjN5OUKzNVg>
A549	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYS3NkBp	NInlWINFVVOR	MorqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgSWdHWi:tLWLhd{Bl\XCnbnTlcpQhcHWvYX6gRVU1QSClZXzsd{B4cXSqIFnDOVAhd2ZiND62NlYh\|ryP	M4O2fFI{Pzl{M{G4
SH-SY5Y	M1vFOWN6fG:2b4jpZ{BCe3OjeR?=		NXzQZmg6PzJiaB?=		NWPsdpNPUUN3ME2xPE4zOSEQvF2=	MVqyN\|g4OTlyOR?=
LoVo	M{nMfGtqdmG\|ZTDBd5NigQ>?		NG\GNWQzKCCq	Mn[5SG1UVw>?	MVfJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB4MjFOwG0>	M1\nXlI{QTNyOUm0
PC9	NUfZeZQ4U2mwYYPlJGF{e2G7		M4L5fVIhcA>?	M4fLfmROW09?	NWX0PG1JUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wNFg4KM7:TR?=	NHzzPIMzOzl\|MEm5OC=>
HCC827	NXHwbYVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH65[WI4OiCq		NGfrenpKSzVyPUCuNFEzKM7:TR?=	NH7kc\|YzOzl5M{G2PC=>
A549	Mn7yT4lv[XOnIFHzd4F6	MVKxJO69VQ>?	NGX2UpQyKGh?	M{j0W2ROW09?	M2HxcWlvcGmkaYTpc44hd2ZiRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{QTlizszN	M3fJ[\|I{QTh6M{W0
A549	M3KxTGZ2dmO2aX;uJGF{e2G7	M{P0N\|Eh\|ryP	NVeyUFdROSCq	NU\xZ4d{TE2VTx?=	NX[1eGwzS2WubIXsZZIhfXC2YXvl	MUmyN\|k5QDN3NB?=
HCC827	NU[3fVNGU2mwYYPlJGF{e2G7	NW\1Z\|ZUOC53IN88US=>	NEPNRlkzKGh?	MkK5SG1UVw>?	NXjLXndnUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=	MlPiNlM6QTN\|Mki=
HCC827	MlLQSpVv[3Srb36gRZN{[Xl?	NVW5eWpTOC53IN88US=>	MW[yJIg>	NU\6UHpyTE2VTx?=	MX3Jcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjDpckBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJGhESzh{NzDj[Yxtew>?	MWGyN\|k6OzN{OB?=
HCC827	M1jhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7uU2lROTBizszN	NWfOO2ZUPzJiaB?=	NInLV5ZFVVOR	Mn3BRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDn[YZqfGmwaXKtd4Vve2m2aY\lJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3KHSxIFG3OVAh\GWuZYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2QDFizszN	Mk\UNlQxPTN4N{S=
A431	NEjabYNMcW6jc3WgRZN{[Xl?	NV7J[ZV[OTByIN88US=>	NEnYWJI{OCCvaX6=		NU\XdXNLUW6qaXLpeIlwdiCxZjDFS2ZTKGmwIIPo[YQhdWWvYoLhcoUhfmW\|aXPs[ZMhf2m2aDDJR\|UxKG:oIEGuNUDPxE1?	MlnMNlQxQTR2M{K=
BCRP-MDCK2	MlKxSpVv[3Srb36gRZN{[Xl?	MkPpNU45KM7:TR?=	NYjINY1FPzJiaB?=	NULCcHR2TE2VTx?=	Mn31TY5kemWjc3Wgc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZR	NXHNWIRJOjRzOESyNVM>
BCRP-MDCK2	NHfMZnVHfW6ldHnvckBCe3OjeR?=	NHn4cFEyNjhizszN	MmPpO\|IhcA>?	NF6wUolFVVOR	M4DS[HJm\HWldHnvckBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?	Mn;oNlQyQDR{MUO=
MDCK	M1zQXmN6fG:2b4jpZ{BCe3OjeR?=		NYO0OlN1PzJiaB?=	MlGxSG1UVw>?	MVjHTVUxRTFwNEWg{txO	M{T5eFI1OTh2MkGz
MDCK2	NEC0fodHfW6ldHnvckBCe3OjeR?=	M4Lm[\|EvQCEQvF2=	Mlu0O\|IhcA>?	MmnJSG1UVw>?	MXXJcohq[mm2aX;uJI9nKGi3bXHuJGJEWlBiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJGhw\WOqc4SgN\|M{PDJiYXPjeY12dGG2aX;uJJdqfGhiSVO1NEBw\iB\|LkG5JO69VQ>?	MYKyOFE5PDJzMx?=
A431	NH\QN4JEgXSxdH;4bYMhSXO\|YYm=		NWfoflFbPzJiaB?=	M3u1fGROW09?	NIjvdlZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGW6cILld5NqdmdiRVfGVkB4cXSqIFnDOVAhd2ZiMD61OUDPxE1?	NFnxSXMzPDRzMUGyNy=>
Calu3	NXr5UnFPS3m2b4TvfIlkKEG\|c3H5		MmDSO\|IhcA>?	MYfEUXNQ	M1faUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNidHV\|IHPlcIx{KGW6cILld5NqdmdiSFXSNkB4cXSqIFnDOVAhd2ZiMD65PUDPxE1?	NV\IflYxOjR2MUGxNlM>
KB	M4W5emtqdmG\|ZTDBd5NigQ>?	MVyxNEDPxE1?	NEDmeIcyKGh?	NVmxXooyTE2VTx?=	M4fXdWlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjDFS2ZTKHerdHigTWM2OCCxZjCwMlAzPSEQvF2=	NUL1OYt{OjR2MUGxNlM>
BEAS2B	MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV61NEDPxE1?	Mn\FO\|IhcA>?	NFHEWJJFVVOR	NHqxRY9KSzVyPUGzMlk1KM7:TR?=	NH7ubHMzPDZyN{W5NS=>
NCI-H1975	NVewdlBmTnWwY4Tpc44hSXO\|YYm=	MnzyNVAxKM7:TR?=	MkXINVUxKG2rbh?=	MUTEUXNQ	NG\UPGhKdmS3Y4Tpc44hd2ZiTl:gdJJw\HWldHnvckBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2gcZV1[W62	NFH0fmMzPDZyN{W5NS=>
Hela	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUKyOEBp	M2[1cmROW09?	M4jm[GlEPTB;Mj62O{DPxE1?	MXyyOFc{OTJ6MR?=
HepG2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXzWcpF[OjRiaB?=	MnvISG1UVw>?	MV3JR\|UxRTZwNEKg{txO	Mnj1NlQ4OzF{OEG=
Sf9	NFf4VmRMcW6jc3WgRZN{[Xl?		M2PMfVExKG2rbh?=	Mn7NSG1UVw>?	M1;rVWlvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBz\WOxbXLpcoFvfCCqaYOteIFo\2WmIFXHSnIhMGGvaX7vJIFkcWRiNkS1MVEyQDZrIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yMjFOwG0>	NVfHeINUOjR5M{GyPFE>
SW620	NYjxZ2VkS3m2b4TvfIlkKEG\|c3H5		M3n0SVQ5KGh?	NUmzU2llTE2VTx?=	MXTJR\|UxRTJ6LkKg{txO	NWXLSGI2OjR7MEC1PVQ>
HCC827	MY\GeY5kfGmxbjDBd5NigQ>?	NIHZZpUxNjVizszN	MXuyJIg>	MX;EUXNQ	NFrZTnhld2W\|IH7veEBqdmirYnn0JIMuVWW2IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbh?=	M2PEXlI{QTl\|M{K4
HCC827	MoDVSpVv[3Srb36gRZN{[Xl?	NG\mR4UxNjVizszN	NIizdY4zKGh?	MW\EUXNQ	M3LQUYRw\XNibn;0JIlvcGmkaYSgZ{1O\XRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyNESvOFIheGixc4Doc5J6dGG2aX;u	M37MVlI{QTl\|M{K4
HCC827	NIm5dJJEgXSxdH;4bYMhSXO\|YYm=	NWHFOXNrOC53IN88US=>	MmPrO\|IhcA>?	M4q2UWROW09?	M3\5TohieyCwbzDjfZRwfG:6aXPpeJk>	MoC5NlM6QTN\|Mki=
NCI-H1975	NX3nbWNDTnWwY4Tpc44hSXO\|YYm=	M3;jWVExKM7:TR?=	NGP6UpE5KGh?	NUD1fFVsTE2VTx?=	NVvvVmw4\G:nczDuc5QhcW6qaXLpeIkhTUeIUjDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRWLLJJBpd3OyaH;yfYxifGmxbh?=	NX[2N2d5OjNzMU[xOlg>
A431	MX3LbY5ie2ViQYPzZZk>	NVu4eWdwOSEQvF2=	MX6xJIg>	M3XlOGROW09?	MUDoZZMhdm9iaYLy[ZZmenOrYnzlJIlvcGmkaYTpc44hd2ZiRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9v	M1jqfFI1QTByNUm0
LNCaP	NXT6b3NpTnWwY4Tpc44hSXO\|YYm=	NWHLd\|JTOTBizszN	MoTmNoghd3JiNDDo	MkDjSG1UVw>?	M2qyWIRw\XNibn;0JIlvcGmkaYSgZZV1d3Cqb4PwbI9zgWyjdHnvckBw\iCrbX31co9xfXKrZnnl[EBndGGpLYTh[4dm\CCEbYigZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcOzKSXVHUVC=>	M3\ZPVE5PjZ5M{Gy
H1975	MlXoT4lv[XOnIFHzd4F6	NF7s[2MyKM7:TR?=	M3jTT\|I1KGh?	M2TtUmROW09?	NH;3Wmhld2W\|IH7veEBqdmirYnn0JGVITlJicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfA>?	NF\aN\|EzPDZyN{W5NS=>
H1975	NXHYZmttTnWwY4Tpc44hSXO\|YYm=	M{jQWlEh\|ryP	M2\lelI1KGh?	M4TwbmROW09?	MmPo[I9meyCwb4SgbY5pcWKrdDDFVmsheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBO	NIT4OWQzPDZyN{W5NS=>
HCC827	NX7sZnFZU2mwYYPlJGF{e2G7	MV6wMlEyKM7:TR?=	NXLuRVJwOSCq	NXqzWpBSTE2VTx?=	NUL3R\|A4cGG\|IH7vJIlzemW4ZYLzbYJt\SCrbnjpZol1cW:wIH;mJGVITlJiYYPz[ZN{\WRiYYOgdoVkd3[ncomgc4YhTUeIUjDheZRweGixc4Doc5J6dGG2aX;u	MWeyOFEzPDh7OB?=
H1975	NG\pZmZMcW6jc3WgRZN{[Xl?	M2fqPFAvOzNizszN	M3iyWFIhcA>?	MkHSSG1UVw>?	MVvkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRWtVKHCqb4PwbI9zgWyjdHnvci=>	NWfid4pxOjRzMkS4PVg>
H1975	MUTLbY5ie2ViQYPzZZk>	NUXYSnM5OC5\|MzFOwG0>	NVL6ZoxZOiCq	MU\EUXNQ	M1zaOIRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	NXX5fZU5OjRzMkS4PVg>
H1975	MYPLbY5ie2ViQYPzZZk>	MoXnNE4{OyEQvF2=	M4\CblIhcA>?	M{SwVGROW09?	MUDkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36=	MYmyOFEzPDh7OB?=
H1975	NXfjWFR4U2mwYYPlJGF{e2G7	MmfYNE4yOjVizszN	MoryNlQhcA>?	M1;ESGROW09?	NHX3[2Vld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?	NGLaOFkzOjN\|OUO0Ni=>
H1975	NE\C[YpMcW6jc3WgRZN{[Xl?	NIPVNJExNjVizszN	NUjLdHRZOjRiaB?=	M1O1b2ROW09?	NYDvbnZn\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDFdosheGixc4Doc5J6dGG2aX;u	M1Pq[VIzOzN7M{Sy
H1975	NU\WfJJDU2mwYYPlJGF{e2G7	NUSyOGpLOC53IN88US=>	Ml3FNlQhcA>?	MYLEUXNQ	M1K1cYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	M{C3RlIzOzN7M{Sy
MIAPaCa2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDJSGEzNjVizszN	MUe3NkBp	NILId25FVVOR	NUj4W456cGG\|IH7vJIdzd3e2aDDpcohq[mm2aX;u	NHXicnQzODR4NkW1OS=>
MIAPaCa2	MXfDfZRwfG:6aXOgRZN{[Xl?	NX;GO5QxOSEQvF2=	NEW4UJAyOCCm	MXHEUXNQ	M{DVeIhieyCwbzDjfZRwfG:6aXPpeJkh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2:ub375JIZwem2jdHnvci=>	NED4R\|gzODR4NkW1OS=>
MIAPaCa2	MmPERZBweHSxc3nzJGF{e2G7	MX6xNEDPxE1?	MkO4NlRpKG:{IES4JIg>	MUfEUXNQ	MoHL[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	NF\JNZMzODR4NkW1OS=>
MIAPaCa2	MVfBdI9xfG:\|aYOgRZN{[Xl?	M3qyWlIxKM7:TR?=	MWCyOEBp	NVHUVlJLTE2VTx?=	Mn7J[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk[XOyYYPlJFMh[WO2aY\heIlwdg>?	MUWyNFQ3PjV3NR?=
EoL-1	NVmwZ\|FvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTVwMUegcm0>	NUTqe2x{W0GQR1XS
NCI-H720	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoK0TWM2OD1{Nj65NkBvVQ>?	NWnIUmJHW0GQR1XS
NCI-SNU-5	NVz5V41tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjqTWM2OD1{OD6xPUBvVQ>?	M1LGW3NCVkeHUh?=
EW-3	NGftTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkP6TWM2OD12Nj6wOEBvVQ>?	M{L3UXNCVkeHUh?=
HCC2218	NI\IVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nMbGlEPTB;NUCuOVkhdk1?	NHLRdVhUSU6JRWK=
HuO-3N1	MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHmdWdKSzVyPUW2MlA6KG6P	NE\PNZpUSU6JRWK=
DB	M2fyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlW1TWM2OD14MD65OkBvVQ>?	NV\mWIdSW0GQR1XS
HSC-4	M{PtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPIVVQ{UUN3ME22NU42OyCwTR?=	MW\TRW5ITVJ?
DOK	NFrEUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HIOGlEPTB;OUOuOlIhdk1?	M2\VbnNCVkeHUh?=
H9	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTF\|Nz6yJI5O	NGSxXlRUSU6JRWK=
NCI-H292	M1z1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTBTWM2OD1zNkKuOlYhdk1?	NYDDR3NbW0GQR1XS
HSC-2	Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPzTWM2OD1zNkWuOVchdk1?	NEn0T\|VUSU6JRWK=
LU-65	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moj3TWM2OD1zNk[uOlEhdk1?	M1jJNnNCVkeHUh?=
BV-173	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTF6Nj61OUBvVQ>?	MmewV2FPT0WU
LB2241-RCC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTF7ND65N{BvVQ>?	Mni4V2FPT0WU
KG-1	M2fFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvGZVl5UUN3ME2yNFQvOzRibl2=	MVPTRW5ITVJ?
CHL-1	MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTJyOD61NUBvVQ>?	M1nIU3NCVkeHUh?=
KYSE-140	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\0TmlEPTB;MkC5Mlk3KG6P	MX\TRW5ITVJ?
DU-145	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\1fWlEPTB;MkG5MlA1KG6P	MoH4V2FPT0WU
EW-13	M4XlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XGfmlEPTB;MkK1MlEhdk1?	MX3TRW5ITVJ?
KYSE-450	NHTtfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3m3OmlEPTB;MkS3MlkzKG6P	NUL5U3dCW0GQR1XS
CAL-72	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGr3[HFKSzVyPUK2PE44OyCwTR?=	MV\TRW5ITVJ?
MEG-01	NFG1bVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEH6OpBKSzVyPUK3Ok44PiCwTR?=	NULhfo0yW0GQR1XS
HCE-T	M{j3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPmTWM2OD1{N{muO\|khdk1?	MmPZV2FPT0WU
NCI-SNU-1	M3Th[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTJ6Mz6zNkBvVQ>?	NVjKbVBqW0GQR1XS
CAL-27	NUHLcWtCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTJ6OT6wPEBvVQ>?	M{\lTHNCVkeHUh?=
BALL-1	NGTzVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fpW2lEPTB;Mkm3MlQzKG6P	NVzmT4RkW0GQR1XS
SBC-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPXTWM2OD1\|MEeuO\|khdk1?	NWW3dm1EW0GQR1XS
CAL-54	M3HMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmryTWM2OD1\|MUGuNlMhdk1?	MXHTRW5ITVJ?
TI-73	NH7KfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LWWGlEPTB;M{GyMlc2KG6P	MYnTRW5ITVJ?
P12-ICHIKAWA	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTXZYdkUUN3ME2zNlgvODZibl2=	M3;ZWXNCVkeHUh?=
ACHN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnkZXFKSzVyPUOzNU41KG6P	NYW3eI5RW0GQR1XS
PC-14	MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnHWXB4UUN3ME2zN\|MvPDFibl2=	NY\OfFhDW0GQR1XS
HCC1806	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fiR2lEPTB;M{O3MlUyKG6P	NVv3PIN6W0GQR1XS
SK-MEL-24	NV3GWFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3iTWM2OD1\|M{euPFchdk1?	MlLTV2FPT0WU
A4-Fuk	NGfOTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\HXmlEPTB;M{WwMlAzKG6P	MV3TRW5ITVJ?
ECC10	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTN3Mj65OkBvVQ>?	MUfTRW5ITVJ?
KASUMI-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELT[VZKSzVyPUO2Ok44OyCwTR?=	NHXYUZdUSU6JRWK=
CAL-33	Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TlTmlEPTB;M{ewMlkhdk1?	NELFNFJUSU6JRWK=
MDA-MB-175-VII	NYT5cYp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jPeWlEPTB;M{e4Mlg5KG6P	NHPVVZZUSU6JRWK=
NUGC-3	Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\sO3RKSzVyPUSwNU45OSCwTR?=	NGXXWGdUSU6JRWK=
KY821	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTRyOD61O{BvVQ>?	M2PQdHNCVkeHUh?=
CTB-1	NVi5bot5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHMWmRKSzVyPUSyOE41KG6P	M1PVcnNCVkeHUh?=
DoTc2-4510	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkT1TWM2OD12NEKuNVIhdk1?	NX7EOWs{W0GQR1XS
EFO-27	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonETWM2OD12NUSuO\|Qhdk1?	MknJV2FPT0WU
BPH-1	NHu3b5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fMemlEPTB;NEmxMlE3KG6P	NWrYRnFbW0GQR1XS
KYSE-270	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVuxSGo1UUN3ME20PVgvPjVibl2=	MWPTRW5ITVJ?
HO-1-N-1	NX\aZ3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3keI5QUUN3ME21NFkvOjVibl2=	NWC2eW5ZW0GQR1XS
SK-MEL-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHDc2dKUUN3ME21NVAvQTlibl2=	MnHJV2FPT0WU
MOLT-13	M2TlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTVzND64NkBvVQ>?	M2myNHNCVkeHUh?=
TK10	MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTVzNT6xNUBvVQ>?	MX;TRW5ITVJ?
HN	M4X0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17yZmlEPTB;NUG3MlM5KG6P	NF7oVGxUSU6JRWK=
SCC-15	M3fSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zieWlEPTB;NUK1MlY5KG6P	NYLOe4lxW0GQR1XS
NCI-H358	M1fyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1O4NmlEPTB;NUK3MlY3KG6P	MULTRW5ITVJ?
KYSE-180	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\PVppKSzVyPUWzNE43OiCwTR?=	M{\GRXNCVkeHUh?=
NCI-H82	NWPhOFlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1[3WGlEPTB;NUSwMlUhdk1?	M2jPVHNCVkeHUh?=
NB7	MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEP1OnZKSzVyPUW0Ok4{OiCwTR?=	MWTTRW5ITVJ?
DSH1	NXX1[nN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTV4Nj64PEBvVQ>?	MY\TRW5ITVJ?
RS4-11	MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUW3[oUyUUN3ME21OlgvPTlibl2=	M37ISXNCVkeHUh?=
CAN	NEDxU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{[0O2lEPTB;NUiwMlc3KG6P	M{X5XXNCVkeHUh?=
Ca9-22	M3PnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3k[ZVDUUN3ME21PFgvPjRibl2=	MYrTRW5ITVJ?
CAL-39	M33TN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTV7Nj6zJI5O	MV;TRW5ITVJ?
NCI-H1623	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\i[2lEPTB;NUm5MlM3KG6P	NVzoc\|NOW0GQR1XS
FADU	NX;zNlNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHGTWM2OD14MESuOlkhdk1?	MY\TRW5ITVJ?
NB69	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjaZmNEUUN3ME22NVQvOzVibl2=	MVnTRW5ITVJ?
Ramos-2G6-4C10	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTZ{MT60OkBvVQ>?	MVTTRW5ITVJ?
LB1047-RCC	M{exSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHkdmt1UUN3ME22NlUvOjlibl2=	M1X2NHNCVkeHUh?=
MV-4-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHURZRQUUN3ME22NlcvPyCwTR?=	MojpV2FPT0WU
DBTRG-05MG	M3TSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVu2NndQUUN3ME22N\|IvOjhibl2=	NX;iPIlsW0GQR1XS
ME-180	NYHFcW9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTZ\|Mj65JI5O	MXvTRW5ITVJ?
NBsusSR	NYLpVGsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILyT45KSzVyPU[0Ok42OiCwTR?=	NITpbXhUSU6JRWK=
COR-L105	NVTuc4RCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmexTWM2OD14NkKuOVMhdk1?	NXv4W4tmW0GQR1XS
ETK-1	NVPvdWl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\yZo9PUUN3ME22OlIvPTlibl2=	MULTRW5ITVJ?
L-363	NEnJd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzvOolkUUN3ME22O\|EvQTRibl2=	NF73U49USU6JRWK=
LU-134-A	NX\ITmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHETWM2OD15MUmuNFkhdk1?	M1Hze3NCVkeHUh?=
NCI-H1770	NInLbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\qOWlEPTB;N{KyMlQhdk1?	MXrTRW5ITVJ?
HAL-01	NWfoN21bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LNUWlEPTB;N{O0MlcyKG6P	NGW4emNUSU6JRWK=
COLO-684	NXPWR2NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XjeGlEPTB;N{WzMlAyKG6P	NYDDR25lW0GQR1XS
TE-6	NFHI[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELjSnZKSzVyPUe2OE4{OSCwTR?=	M{nvS3NCVkeHUh?=
A431	M4DWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLpTWM2OD15OECuNFQhdk1?	NIK0R5JUSU6JRWK=
LU-135	NGOwNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\WTWM2OD15OEOuNFMhdk1?	MoXhV2FPT0WU
EC-GI-10	NX3BRWFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLmVGRKSzVyPUe4PE42OiCwTR?=	MYrTRW5ITVJ?
TE-12	MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkniTWM2OD16MkGuNVEhdk1?	NUjxfotOW0GQR1XS
LoVo	MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLoUo9KSzVyPUi1PU4xPiCwTR?=	NFz5dY5USU6JRWK=
23132-87	NGXxPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnMXZhKUUN3ME24OlQvOjhibl2=	MlvOV2FPT0WU
AU565	M2DY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrFb45DUUN3ME24OlkvPiCwTR?=	MWHTRW5ITVJ?
DEL	Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Hq[mlEPTB;OEe3MlY2KG6P	NFr3cFRUSU6JRWK=
COR-L88	M3LRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTaTWM2OD16OEKuNlYhdk1?	MkDsV2FPT0WU
NCI-H2126	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPqbWRKSzVyPUi4Nk45OyCwTR?=	Mn:wV2FPT0WU
CAPAN-1	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPyXFdKSzVyPUi4N{4zQSCwTR?=	NHH0bpJUSU6JRWK=
BT-474	M13jbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXGcnZKSzVyPUmzPE4yPCCwTR?=	MX\TRW5ITVJ?
BHY	NEmxSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4[xdGlEPTB;OUe1MlQ5KG6P	M2H0Z3NCVkeHUh?=
HT-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fZS2lEPTB;OUiyMlQyKG6P	MYPTRW5ITVJ?
SK-NEP-1	M{OxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jlU2lEPTB;OUi5MlQ1KG6P	MoPoV2FPT0WU
MS-1	NEiyenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXOTWM2OD17OUSuOlkhdk1?	MlS5V2FPT0WU
DOHH-2	M{PQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTFwMECwNlEh\|ryP	Mme4V2FPT0WU
NCI-H1304	NInnPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfSTWM2OD1zLkCxOlQ{KM7:TR?=	MmD0V2FPT0WU
EM-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTFwMEOwNVYh\|ryP	NULXbJhTW0GQR1XS
MHH-PREB-1	NFLGV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HhbWlEPTB;MT6wPFQ2OSEQvF2=	M3P5dHNCVkeHUh?=
KU-19-19	M2HNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;IeGlEPTB;MT6wPFU1OSEQvF2=	Mk[1V2FPT0WU
NCI-H1648	MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLuUGJGUUN3ME2xMlExPjF4IN88US=>	MkW2V2FPT0WU
MKN1	NHnLW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTFwMkG5PFch\|ryP	NFr2dVhUSU6JRWK=
SNU-449	M2LDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\FfWlEPTB;MT6yNlIxQCEQvF2=	NVrWe5ZTW0GQR1XS
OAW-42	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTFwMke4NlUh\|ryP	NV;ONVZ6W0GQR1XS
769-P	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\wTWM2OD1zLkK3PVE5KM7:TR?=	NGHzdGVUSU6JRWK=
SW1088	M2flXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnyyTWM2OD1zLkK5OlA4KM7:TR?=	NGrHNHZUSU6JRWK=
GCIY	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTFwM{CxN\|Ih\|ryP	Mo\2V2FPT0WU
CTV-1	NV3PbGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPyTWM2OD1zLkOwPEDPxE1?	MU\TRW5ITVJ?
NCI-H1092	NH\JbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTFwM{C4OUDPxE1?	MlHCV2FPT0WU
NKM-1	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jGU2lEPTB;MT6zNlU6PyEQvF2=	NGH5bWFUSU6JRWK=
NCI-H1650	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoP1TWM2OD1zLkOzOFgzKM7:TR?=	NGTpTHhUSU6JRWK=
SW954	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTFwM{SwOFgh\|ryP	M4TTbXNCVkeHUh?=
SW48	NEnRcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoGxTWM2OD1zLkO2OlE5KM7:TR?=	M{HYZ3NCVkeHUh?=
SK-N-DZ	NVnFOXlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\ydm1[UUN3ME2xMlM3QTR5IN88US=>	M3\uTXNCVkeHUh?=
KMOE-2	M1vETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PTVWlEPTB;MT6zPVgyPSEQvF2=	M1r4W3NCVkeHUh?=
NB5	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTjV3FKSzVyPUGuOFA5QTRizszN	NUe1SI5sW0GQR1XS
CCRF-CEM	NELEbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\WVWlEPTB;MT60NVEyKM7:TR?=	NIWyOVRUSU6JRWK=
RH-1	NGCyVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3Lu[mlEPTB;MT60NVE{PiEQvF2=	MmDtV2FPT0WU
NCI-H526	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwNEO4NlYh\|ryP	NEHVVmFUSU6JRWK=
697	NHHSdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoCzTWM2OD1zLkS0NVA1KM7:TR?=	MkL2V2FPT0WU
J82	NVPIVoQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTFwNEW3OlYh\|ryP	MXnTRW5ITVJ?
BE-13	MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\RWoFKSzVyPUGuOVA3PzFizszN	NXzjdodEW0GQR1XS
SAS	NEG0UoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHofldKSzVyPUGuOVE3OjJizszN	M4K3ZnNCVkeHUh?=
SCC-25	NV3HZo04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFyxTVlKSzVyPUGuOVI{OjJizszN	MnLXV2FPT0WU
LAMA-84	NWjRPJpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFwNUO4NVUh\|ryP	MV;TRW5ITVJ?
HSC-3	M2nLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2H0UmlEPTB;MT61OFM5KM7:TR?=	NHTwUXFUSU6JRWK=
BT-549	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFH6UoNKSzVyPUGuOVg4PDdizszN	NHHhVWFUSU6JRWK=
ML-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTPU2tKSzVyPUGuOlQxOjlizszN	NIDCdYhUSU6JRWK=
BB30-HNC	NGjvXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoS2TWM2OD1zLk[4PVczKM7:TR?=	NVrLN3A6W0GQR1XS
PANC-03-27	M1;uSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPQTWM2OD1zLkewNVM6KM7:TR?=	NGPMdVFUSU6JRWK=
COLO-678	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTFwN{O0OFQh\|ryP	NXXDO4RNW0GQR1XS
NCI-H1666	NGOxdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLoTodKSzVyPUGuO\|Q4ODRizszN	NYTK[Yo4W0GQR1XS
NCI-H209	NYX3fWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTZPY9KSzVyPUGuO\|czPjlizszN	MnvUV2FPT0WU
EPLC-272H	NVXibZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrITWM2OD1zLki1OVQ6KM7:TR?=	MYPTRW5ITVJ?
OMC-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fVZWlEPTB;MT65PVg5QCEQvF2=	MWXTRW5ITVJ?
HCC70	NYmzUIZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzuTWM2OD1{LkCwPFE2KM7:TR?=	NWDYdXpDW0GQR1XS
CAL-12T	NFK5PHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUW5[4hHUUN3ME2yMlAyQDZzIN88US=>	NVThc4VVW0GQR1XS
TGBC24TKB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7YXpk3UUN3ME2yMlAzQTZzIN88US=>	MorUV2FPT0WU
EKVX	NWnz[Zc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofITWM2OD1{LkC0PVM6KM7:TR?=	MUfTRW5ITVJ?
SW1116	NXHRdW1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfsToRKSzVyPUKuNFYxODlizszN	NF24V49USU6JRWK=
NCI-H2009	NX\BZmNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\kTWM2OD1{LkC2NlE1KM7:TR?=	MV3TRW5ITVJ?
RPMI-8866	NW\6PWp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVSwR5hnUUN3ME2yMlA5PDhzIN88US=>	NYO0UIFsW0GQR1XS
KARPAS-45	MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXlUFFKSzVyPUKuNVI1PzlizszN	NH3Z[pBUSU6JRWK=
RXF393	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoO0TWM2OD1{LkGzNFM3KM7:TR?=	MY\TRW5ITVJ?
786-0	NIS5WVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPDTWM2OD1{LkG4OFA3KM7:TR?=	MUPTRW5ITVJ?
SCC-4	NIHXd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjoNHZ[UUN3ME2yMlIyPzd4IN88US=>	MkO5V2FPT0WU
BT-20	MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2eyZWlEPTB;Mj6yOlc1PCEQvF2=	MYHTRW5ITVJ?
A498	NEHBdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTJwMkm0NVUh\|ryP	NYG2U4FwW0GQR1XS
IGROV-1	NXziRoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjjTWM2OD1{LkOxNlM4KM7:TR?=	MorpV2FPT0WU
JVM-3	Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\CTWM2OD1{LkO0OlQ{KM7:TR?=	NWDHZoRZW0GQR1XS
NCI-H2170	MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWX3UJdbUUN3ME2yMlM1Pzh\|IN88US=>	NHm2[FNUSU6JRWK=
EW-18	NFXrcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\vU4pVUUN3ME2yMlM2PDdzIN88US=>	NF;iVFVUSU6JRWK=
KU812	NUnJeYUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXX0OlJGUUN3ME2yMlM3Pzd7IN88US=>	M370ZXNCVkeHUh?=
NY	NWDuW2szT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7obZN2UUN3ME2yMlM4OjdizszN	NV;4S2xFW0GQR1XS
HTC-C3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zkZmlEPTB;Mj60NlI3PyEQvF2=	M{C2OXNCVkeHUh?=
CFPAC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\WO2xKSzVyPUKuOFM5PjRizszN	M1TCZ3NCVkeHUh?=
HH	NVizSVVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3qySmlEPTB;Mj60PVg2PCEQvF2=	MXLTRW5ITVJ?
MKN7	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTJwNkK3OFgh\|ryP	NVS1Tm5JW0GQR1XS
TE-8	M1TBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnUVYlTUUN3ME2yMlY{PjV\|IN88US=>	M4PvcHNCVkeHUh?=
MC-IXC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHZTWM2OD1{Lk[0OFU{KM7:TR?=	NVLUdZZFW0GQR1XS
DMS-79	MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEe5eZNKSzVyPUKuOlkzQDRizszN	MoP1V2FPT0WU
Detroit562	M3zWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGe0cpZKSzVyPUKuOlk5PDVizszN	MXfTRW5ITVJ?
HuP-T4	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{SwdmlEPTB;Mj63NlgyQCEQvF2=	M{[xfHNCVkeHUh?=
QIMR-WIL	NXfO[GMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnDXIZPUUN3ME2yMlc2QTV{IN88US=>	Mne2V2FPT0WU
BB65-RCC	NELxXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;nbI5KSzVyPUKuPFA4OTNizszN	NWHMZ3FuW0GQR1XS
PC-3	NVLxVoZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnT6TWM2OD1{LkizN\|E4KM7:TR?=	NYLm[mhlW0GQR1XS
OVCAR-3	NWWxU4tkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mki0TWM2OD1{Lki1OVk1KM7:TR?=	NHS1T5FUSU6JRWK=
KYSE-510	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTJwOE[3PFYh\|ryP	NGfsSG9USU6JRWK=
HC-1	M2jVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDpbXE6UUN3ME2yMlk1ODF{IN88US=>	MlmxV2FPT0WU
NCI-H1693	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGO5bGZKSzVyPUKuPVU5QTdizszN	NFnDPVJUSU6JRWK=
DU-4475	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3tTWM2OD1{Lkm5NFUzKM7:TR?=	MXnTRW5ITVJ?
COLO-680N	NFTifFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTNwMEC0PVUh\|ryP	NGnV[ZFUSU6JRWK=
MN-60	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTNwMES5O\|Qh\|ryP	M1fSSHNCVkeHUh?=
BCPAP	Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Tlc2lEPTB;Mz6wPFI6PSEQvF2=	NYX6bGRSW0GQR1XS
647-V	MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoO5TWM2OD1\|LkG2NlIh\|ryP	NIW3S4lUSU6JRWK=
HT-1376	M1PxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvsb4QxUUN3ME2zMlIxPTB4IN88US=>	M3\NWHNCVkeHUh?=
NCI-H1793	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTNwMkGwPVgh\|ryP	MXrTRW5ITVJ?
SW1463	NVPXdFVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M333W2lEPTB;Mz6yOlE6OiEQvF2=	M2P1PXNCVkeHUh?=
NCI-H727	NXrN[nROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTNwM{i1PFQh\|ryP	NUfofmZ[W0GQR1XS
LB771-HNC	NVe4dXBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofpTWM2OD1\|LkO5NVI3KM7:TR?=	MWDTRW5ITVJ?
D-542MG	M4jH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTNwNESyNlIh\|ryP	MVnTRW5ITVJ?
NTERA-S-cl-D1	M1\ET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPQOndFUUN3ME2zMlQ1QTV5IN88US=>	NGrBNFRUSU6JRWK=
C8166	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYWwTnZIUUN3ME2zMlQ3PTJzIN88US=>	Mn\JV2FPT0WU
639-V	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTNwNUe3PVIh\|ryP	NWXXZYZ{W0GQR1XS
TE-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVznfVR3UUN3ME2zMlU6OTZ7IN88US=>	NHjYfndUSU6JRWK=
OAW-28	NYTmPGpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjNSYU2UUN3ME2zMlU6PDJ4IN88US=>	NVjKeXJVW0GQR1XS
SK-LU-1	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr2SIVKSzVyPUOuOlA3PDVizszN	MVrTRW5ITVJ?
CaR-1	MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTNwNkGwOFgh\|ryP	NE[1cYlUSU6JRWK=
A2780	NFP0OIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHWwdmVKSzVyPUOuOlQxQDlizszN	Ml\IV2FPT0WU
C2BBe1	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTsW4tKSzVyPUOuOlQ1ODdizszN	MXvTRW5ITVJ?
SK-MES-1	M1W0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIr5XnRKSzVyPUOuOlQ3OTRizszN	M{\PNnNCVkeHUh?=
PANC-10-05	NWHucVhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTNwN{KwO\|Ih\|ryP	MWTTRW5ITVJ?
J-RT3-T3-5	NGizXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrITGtQUUN3ME2zMlc2PDB4IN88US=>	MWHTRW5ITVJ?
ES4	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfMfmtPUUN3ME2zMlgzOjh4IN88US=>	NUPKU\|NPW0GQR1XS
NCI-H28	NGHpSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fjd2lEPTB;Mz64Nlk3OSEQvF2=	MVLTRW5ITVJ?
NCI-H1155	NIjJNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvHNmlbUUN3ME2zMlg1OTV7IN88US=>	M{\yWHNCVkeHUh?=
KURAMOCHI	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XKOWlEPTB;Mz64OlA2PiEQvF2=	NU[xSnBEW0GQR1XS
NCI-H69	M4Xobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELXSoVKSzVyPUOuPVAyPzhizszN	M{DiNnNCVkeHUh?=
IST-MES1	M2XleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTNwOUSwNlkh\|ryP	MkDCV2FPT0WU
NH-12	NX3LTZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nSXGlEPTB;Mz65OFE5PyEQvF2=	MnLiV2FPT0WU
JVM-2	NYrZWmJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1ywNmlEPTB;Mz65OFc2OiEQvF2=	M1jUd3NCVkeHUh?=
EW-16	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXaWWxGUUN3ME2zMlk2PTd5IN88US=>	NXLtUFBYW0GQR1XS
NCI-H441	NGHkbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NImxOlBKSzVyPUOuPVcxOTRizszN	M2fyU3NCVkeHUh?=
RCC10RGB	M{X0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTRwMEGyOFYh\|ryP	MYjTRW5ITVJ?
TCCSUP	NWX1OJdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\XbGlEPTB;ND6xNVA2KM7:TR?=	NYDh[IV1W0GQR1XS
HL-60	NFrHfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjhUYRKSzVyPUSuNVIzPDFizszN	MmnWV2FPT0WU
EW-11	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NISyUYZKSzVyPUSuNVMzPjFizszN	MVnTRW5ITVJ?
KARPAS-299	M3fERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTRwM{GwNVMh\|ryP	M1;3[nNCVkeHUh?=
SNU-C2B	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnkRmhKSzVyPUSuN\|Q3QDZizszN	NF\MVnJUSU6JRWK=
LU-139	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Ly[2lEPTB;ND6zO\|I1PyEQvF2=	MmG3V2FPT0WU
HCC1937	NYjXO2tpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nQUmlEPTB;ND6zO\|k6OyEQvF2=	MnjZV2FPT0WU
GR-ST	NHTiVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGCzT2FKSzVyPUSuOFMyQCEQvF2=	NWjXOYVqW0GQR1XS
SK-OV-3	NEO4emNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTRwNE[wOFIh\|ryP	NEDDUHJUSU6JRWK=
A172	NYfjcoVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvuNVBKSzVyPUSuOVU2OjFizszN	MkjmV2FPT0WU
NB10	NI\6S2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrlTWM2OD12LkW5O\|gyKM7:TR?=	NXqy[odGW0GQR1XS
P30-OHK	M2GydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPncGlKSzVyPUSuPFE6OjlizszN	MVjTRW5ITVJ?
KYSE-520	M1X2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LDRmlEPTB;ND64PFAyQCEQvF2=	M{Py[nNCVkeHUh?=
KNS-62	NV62eI9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHMVpBwUUN3ME20MlkxQDB5IN88US=>	MnH0V2FPT0WU
ES1	NEjoV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTRwOU[wN\|Uh\|ryP	M1vre3NCVkeHUh?=
KOSC-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLNTWM2OD12Lkm5PVU6KM7:TR?=	MVfTRW5ITVJ?
TE-9	M2PWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;pcplwUUN3ME21MlAyPTJ3IN88US=>	MoLOV2FPT0WU
NCI-H1838	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTVwMEKwO\|Yh\|ryP	Mmi5V2FPT0WU
KP-N-YN	M2jxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTVwMUK1PVEh\|ryP	MmPHV2FPT0WU
ALL-PO	NIPNc\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PwW2lEPTB;NT6yNlU5PyEQvF2=	NUW0U5psW0GQR1XS
NOMO-1	M1XkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofVTWM2OD13LkKzNVc3KM7:TR?=	M{TJWXNCVkeHUh?=
CGTH-W-1	NIHTfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnFTWM2OD13LkO4OVg1KM7:TR?=	MULTRW5ITVJ?
ATN-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjpfVFKSzVyPUWuOFEyQDRizszN	MV;TRW5ITVJ?
AGS	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEm0WY9KSzVyPUWuOFk3OThizszN	NYjhc4N2W0GQR1XS
SW13	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLrbmkyUUN3ME21MlU{OjZ3IN88US=>	MYnTRW5ITVJ?
SW1990	Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\WVmlEPTB;NT62NlI5PSEQvF2=	MnjEV2FPT0WU
BFTC-905	NFH3TpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jy[2lEPTB;NT62OVg4QCEQvF2=	NF7Cb5RUSU6JRWK=
RMG-I	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVeyUmE3UUN3ME21MlY2QTR{IN88US=>	MkjKV2FPT0WU
HD-MY-Z	M3TRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HSdWlEPTB;NT62PFU5OSEQvF2=	NUTVNoo6W0GQR1XS
HCC1187	M33Gemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPifHFxUUN3ME21MlcyODN{IN88US=>	MoDaV2FPT0WU
HCC2998	NELYU\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjGVlViUUN3ME21MlcyQDd5IN88US=>	MYnTRW5ITVJ?
RT-112	MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPTTWM2OD13LkmwNlQ2KM7:TR?=	Mm\4V2FPT0WU
CAKI-1	NIDnPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTZwMEC5PFUh\|ryP	NGTYTZpUSU6JRWK=
HDLM-2	NXSxXHZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fkNmlEPTB;Nj6wNVQ5QSEQvF2=	MYDTRW5ITVJ?
TE-10	NITJN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLWTWM2OD14LkC0PFM{KM7:TR?=	MmHyV2FPT0WU
KE-37	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fER2lEPTB;Nj6wO\|I2QCEQvF2=	Mn\XV2FPT0WU
RCM-1	M1Hndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEO3XYpKSzVyPU[uNFc4OTlizszN	NILWW5BUSU6JRWK=
Mewo	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILhOY9KSzVyPU[uNVE1QDdizszN	MljYV2FPT0WU
L-428	NYLpSFB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTSTWM2OD14LkG4NFM4KM7:TR?=	NHnJVWVUSU6JRWK=
8-MG-BA	NYqx[YtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTZ[pJkUUN3ME22MlE6Ozd7IN88US=>	NF3ENpdUSU6JRWK=
SK-MEL-28	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoW1TWM2OD14LkKwPVY4KM7:TR?=	NFK1cHRUSU6JRWK=
VA-ES-BJ	M{XIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzLfIhKSzVyPU[uN\|A1PjJizszN	M{DROnNCVkeHUh?=
CAL-120	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nFdGlEPTB;Nj60OVE3OiEQvF2=	NWXMbpUyW0GQR1XS
GAMG	NYf0WY9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDjZnFKSzVyPU[uOVA3OiEQvF2=	NUeyV3BpW0GQR1XS
MSTO-221H	NFy0NGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTZwNUGxO{DPxE1?	NIDLUW9USU6JRWK=
GCT	M3PmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLSdZBkUUN3ME22MlU{Ozh5IN88US=>	NUeyW4ZQW0GQR1XS
SH-4	Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXXTWM2OD14LkW4PFQ1KM7:TR?=	NU\i[WtxW0GQR1XS
Calu-3	M37TOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\yVWlEPTB;Nj62OVU3QCEQvF2=	MmjzV2FPT0WU
SK-HEP-1	Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTZwN{G3OVMh\|ryP	MXrTRW5ITVJ?
PFSK-1	NGTtdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYT3RplJUUN3ME22Mlc{PDd6IN88US=>	MXPTRW5ITVJ?
NB12	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj6O\|VKSzVyPU[uO\|g1ODRizszN	MVPTRW5ITVJ?
A388	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTZwOEm1NkDPxE1?	MoLnV2FPT0WU
KLE	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrJU2tKSzVyPU[uPVY2OTZizszN	NF;2PWRUSU6JRWK=
TE-11	NHnXcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTdwMES5Olch\|ryP	NELpSpRUSU6JRWK=
NCI-H2405	M4DxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnrR2ZKSzVyPUeuNFg{QTNizszN	NVXaZo9RW0GQR1XS
OVCAR-4	NIG0VoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;uO2lEPTB;Nz6xOVM2KM7:TR?=	MVPTRW5ITVJ?
KP-N-YS	M2rub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXwOodwUUN3ME23MlE5OTRizszN	NGLQcYZUSU6JRWK=
NOS-1	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLmTWM2OD15LkK1PFI5KM7:TR?=	NFuzUYVUSU6JRWK=
DMS-114	M2LudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnVTWM2OD15LkK5OlMyKM7:TR?=	NGH3dGZUSU6JRWK=
NCI-H2030	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTdwM{O2PVgh\|ryP	M2PLWHNCVkeHUh?=
HEL	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTdwM{e1NlEh\|ryP	MYrTRW5ITVJ?
CAL-62	MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWK1SGczUUN3ME23MlM6QDZ4IN88US=>	M4rvOnNCVkeHUh?=
COLO-668	M{nZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\PS25wUUN3ME23MlQ{QTZ5IN88US=>	M{e0cXNCVkeHUh?=
SKG-IIIa	M3HzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTdwNEWzPFEh\|ryP	NVfSfYxnW0GQR1XS
HCC1419	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTdwNE[4N\|Mh\|ryP	NHvoWHhUSU6JRWK=
OS-RC-2	M4K0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTdwNEm4PVQh\|ryP	NVPyOlRsW0GQR1XS
COLO-829	NGTqeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPNTWM2OD15Lk[2OFY{KM7:TR?=	NHfVN25USU6JRWK=
NB13	NEm2R\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTdwOEK2Olch\|ryP	MkTYV2FPT0WU
DK-MG	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkOyTWM2OD15LkizNlAyKM7:TR?=	M{jKPHNCVkeHUh?=
SHP-77	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojnTWM2OD15Lki2OlU{KM7:TR?=	Moi0V2FPT0WU
NCI-H661	NWPCXolNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRThwMEW4Olch\|ryP	NH3aZnBUSU6JRWK=
AM-38	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDuTWM2OD16LkG2Nlgh\|ryP	MWrTRW5ITVJ?
VM-CUB-1	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rBZWlEPTB;OD6xO\|AzQSEQvF2=	NHPFTWtUSU6JRWK=
KYSE-70	MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DGSGlEPTB;OD6xPVc3OSEQvF2=	MXHTRW5ITVJ?
5637	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRThwM{GwOVUh\|ryP	M1vDRnNCVkeHUh?=
TGBC11TKB	NFW1cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4WydWlEPTB;OD60OlE3PCEQvF2=	MnXjV2FPT0WU
EGI-1	MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLYcGRKSzVyPUiuOlAxQDhizszN	NWH1bpMzW0GQR1XS
D-392MG	NILLbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmWwTWM2OD16Lk[2NlE1KM7:TR?=	NWjHclI1W0GQR1XS
A673	NYXxRWVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRThwNke2NVEh\|ryP	NYnSeYNoW0GQR1XS
COLO-792	MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fGdWlEPTB;OD63OFk1PiEQvF2=	MoDKV2FPT0WU
NCI-H1792	M1S1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoX3TWM2OD16Lki4PVA{KM7:TR?=	Mne4V2FPT0WU
LS-1034	NWriZYIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LOTmlEPTB;OD65OFY2OiEQvF2=	NH7SSGFUSU6JRWK=
D-566MG	NVnJeFVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\HS4tnUUN3ME25MlAyQDFizszN	MmPoV2FPT0WU
NCI-H226	NX\HPZkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXFTWM2OD17LkC5JO69VQ>?	NWHJSG55W0GQR1XS
ChaGo-K-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13DdmlEPTB;OT6xNFU4QSEQvF2=	MX7TRW5ITVJ?
NCI-H2228	NWfCeY9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXP[2RiUUN3ME25MlEyODhzIN88US=>	NGe3NHpUSU6JRWK=
RPMI-8226	NX;uPZhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLNO3FEUUN3ME25MlEyOzB2IN88US=>	NHPRS25USU6JRWK=
BFTC-909	NXzqeGpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnuxTWM2OD17LkG4Nlk4KM7:TR?=	NGC4ToJUSU6JRWK=
HPAF-II	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnDdnpKSzVyPUmuNlI2OThizszN	M2fvXXNCVkeHUh?=
Capan-2	NVjLOYIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LqSWlEPTB;OT60NFExQSEQvF2=	MlvYV2FPT0WU
IA-LM	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWf4[WN3UUN3ME25MlQyQTZ4IN88US=>	MkHsV2FPT0WU
KP-4	NF\uZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\vNFVNUUN3ME25MlQ5QDN6IN88US=>	MWXTRW5ITVJ?
A101D	NELHZ\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfte\|lqUUN3ME25MlUyPzF7IN88US=>	NUPWUnM3W0GQR1XS
EFO-21	NGXWUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\BeppnUUN3ME25MlU5PzN3IN88US=>	M1:zR3NCVkeHUh?=
C32	NIXnSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33RdGlEPTB;OT62N\|M1KM7:TR?=	NHHw[mJUSU6JRWK=
SW837	NXPDVmhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HWZmlEPTB;OT64OFgzKM7:TR?=	MWjTRW5ITVJ?
OCI-AML2	M2fhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH34d5FKSzVyPUmuPFY6PiEQvF2=	M{SxRXNCVkeHUh?=
NCI-H1355	MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnGXoVKSzVyPUmuPVQxQDhizszN	NGnoPYRUSU6JRWK=
NCI-H2342	NHTJfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvySo5KSzVyPUGwMlAyPTVizszN	NGTqfIFUSU6JRWK=
A204	MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnL3TWM2OD1zMD6wOFY3KM7:TR?=	MXnTRW5ITVJ?
CAL-51	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7wZZprUUN3ME2xNE4xQDd5IN88US=>	Mn\jV2FPT0WU
HCE-4	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\XWIVKSzVyPUGwMlEyOjJizszN	M3nDcXNCVkeHUh?=
NCI-H810	M4Tw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFyLkG1PVch\|ryP	NGX3WYdUSU6JRWK=
DJM-1	MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrNU3Z5UUN3ME2xNE4yPzN{IN88US=>	NGXMRYZUSU6JRWK=
SK-UT-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HzbGlEPTB;MUCuNlU4PCEQvF2=	NX3mcJFlW0GQR1XS
U031	M3PKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;SfWlEPTB;MUCuNlY5PiEQvF2=	NGXQWXlUSU6JRWK=
YH-13	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUm2[oE3UUN3ME2xNE4{ODV5IN88US=>	MnrnV2FPT0WU
K5	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvtTWM2OD1zMD6zN\|k2KM7:TR?=	NVnpb\|MyW0GQR1XS
HEC-1	NHHGSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3W2R2lEPTB;MUCuOFA5OSEQvF2=	M1mxWnNCVkeHUh?=
A2058	M4fJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\GXGlEPTB;MUCuOVQ6OSEQvF2=	MUjTRW5ITVJ?
SW962	NWOyfppHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTFyLk[yNFQh\|ryP	MkXsV2FPT0WU
VMRC-RCZ	M2H4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTFyLk[3OFkh\|ryP	MVPTRW5ITVJ?
D-336MG	M4\BXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7OTWM2OD1zMD63NFA2KM7:TR?=	NInJZ5JUSU6JRWK=
LXF-289	M4jxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7IdIl6UUN3ME2xNE44QTZ5IN88US=>	M1zhfnNCVkeHUh?=
SW900	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjPTWM2OD1zMD64NlI5KM7:TR?=	MlPTV2FPT0WU
K-562	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTFyLkizPVUh\|ryP	MnTIV2FPT0WU
HCC38	M4r6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M16xT2lEPTB;MUCuPVcyPiEQvF2=	MXXTRW5ITVJ?
SF-295	NYrXRYE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvlNZFKSzVyPUGwMlk6ODJizszN	MnH4V2FPT0WU
LB831-BLC	NWLRV2p7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzSRWZNUUN3ME2xNU4zPTV4IN88US=>	Ml;qV2FPT0WU
FTC-133	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfWXo1CUUN3ME2xNU4{ODhzIN88US=>	NULT[25pW0GQR1XS
HCC1954	NXGyRldnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTFzLkSzOkDPxE1?	NH3Ie25USU6JRWK=
GOTO	NI\0SHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1P2cWlEPTB;MUGuOVIxPiEQvF2=	M2PJT3NCVkeHUh?=
LS-411N	NVHaSZhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzGV2VJUUN3ME2xNU43OTBzIN88US=>	NVPKU5J4W0GQR1XS
RPMI-7951	Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDvTWM2OD1zMT62N\|Q5KM7:TR?=	NVPEOmNSW0GQR1XS
NCI-H1299	NFWyW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILaWIxKSzVyPUGxMlY3PDdizszN	Mom4V2FPT0WU
MLMA	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fRVGlEPTB;MUGuOlk6PyEQvF2=	MlnCV2FPT0WU
MMAC-SF	NF\s[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M16ySGlEPTB;MUGuO\|I2OiEQvF2=	M3LBWXNCVkeHUh?=
UM-UC-3	NUHMblRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTWeJVEUUN3ME2xNU44PDJzIN88US=>	MUTTRW5ITVJ?
SCC-9	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXPbnNKSzVyPUGxMlgyPTFizszN	NETMZ45USU6JRWK=
HOS	Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYm4SYI4UUN3ME2xNU45Pjh\|IN88US=>	NIm0d\|dUSU6JRWK=
OE19	NVLxNXNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTFzLkmzOlch\|ryP	MVHTRW5ITVJ?
Mo-T	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTFzLkm1OFEh\|ryP	MknGV2FPT0WU
CAMA-1	M37TOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHpfIhbUUN3ME2xNk4yPjN\|IN88US=>	MYrTRW5ITVJ?
U-118-MG	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXT4[IZ1UUN3ME2xNk4zPDRzIN88US=>	MnLxV2FPT0WU
KS-1	M2m2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LhXWlEPTB;MUKuNlg{OiEQvF2=	MX7TRW5ITVJ?
JAR	NXPQdopWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LWRmlEPTB;MUKuN\|M3QSEQvF2=	NVPVeVdKW0GQR1XS
ABC-1	NX3r[mNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTF{LkO0NUDPxE1?	Mki4V2FPT0WU
Daoy	M1;nNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fPXWlEPTB;MUKuOFU1OiEQvF2=	M{f3dHNCVkeHUh?=
C3A	NYXLZZFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\senhvUUN3ME2xNk42Pzh3IN88US=>	MlHJV2FPT0WU
GT3TKB	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\KXIVkUUN3ME2xNk43OzJ5IN88US=>	Mn6wV2FPT0WU
DMS-273	MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTF{Lki2N\|Mh\|ryP	Mn\SV2FPT0WU
G-361	MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTF{LkmxNlkh\|ryP	NGH1V3JUSU6JRWK=
RH-18	NXu4TJNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\0TWM2OD1zMz6yPVYzKM7:TR?=	MWHTRW5ITVJ?
SN12C	M3LX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DnU2lEPTB;MUOuN\|gxQCEQvF2=	NU\XUItEW0GQR1XS
NCI-H1993	NYXtWnRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGK2N\|hKSzVyPUGzMlQzQDVizszN	M2DOTHNCVkeHUh?=
LOXIMVI	NGLkUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHu0e2dKSzVyPUGzMlYyPTFizszN	M4TqOHNCVkeHUh?=
SK-PN-DW	NUmwcZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTF\|Lki0Nlch\|ryP	MXrTRW5ITVJ?
KALS-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofqTWM2OD1zMz64OVI2KM7:TR?=	NETQWpBUSU6JRWK=
LAN-6	M2DweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF2LkK1N{DPxE1?	NEK1c2VUSU6JRWK=
A549	NULQcndVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlruTWM2OD1zND60O\|EzKM7:TR?=	M2fnTHNCVkeHUh?=
RD	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{T2cmlEPTB;MUSuOFgyOyEQvF2=	NV\0e4R7W0GQR1XS
TGBC1TKB	MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljJTWM2OD1zND62OlE2KM7:TR?=	NIKxTVFUSU6JRWK=
NCI-H630	NEezd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;LTWM2OD1zND65OFY4KM7:TR?=	MVvTRW5ITVJ?
MIA-PaCa-2	NIOycXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XZO2lEPTB;MUSuPVY6KM7:TR?=	NX3XW\|h{W0GQR1XS
NCI-H1755	NGrBd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrOTWM2OD1zND65PVU{KM7:TR?=	M4XGUnNCVkeHUh?=
MOLT-4	NFvoUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXzTpJRUUN3ME2xOU4xPDl5IN88US=>	NHvWNpBUSU6JRWK=
CW-2	NH7EcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrIW2J3UUN3ME2xOU4yPDJzIN88US=>	M3XkNXNCVkeHUh?=
COLO-320-HSR	M2S0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUn1fXI4UUN3ME2xOU42OzB5IN88US=>	MUPTRW5ITVJ?
UMC-11	NWf0UlVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33kNmlEPTB;MUWuO\|UzOyEQvF2=	MlraV2FPT0WU
MCF7	MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrKPXNKSzVyPUG1MlgyPDVizszN	NFq4eIdUSU6JRWK=
NCI-H23	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnUTWM2OD1zNT64OFM5KM7:TR?=	M{HFd3NCVkeHUh?=
HuCCT1	M{PKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYCwSJo{UUN3ME2xOU45PzRizszN	M{DQUXNCVkeHUh?=
MPP-89	NUnzTJpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33TR2lEPTB;MUWuPVQyPyEQvF2=	MV3TRW5ITVJ?
HT55	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvDfW9QUUN3ME2xOU46PDd6IN88US=>	NWq5ZXFlW0GQR1XS
no-11	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTF3Lkm2OlMh\|ryP	MWfTRW5ITVJ?
GP5d	NX7aUZpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M32yb2lEPTB;MU[uNlE5PyEQvF2=	MnjIV2FPT0WU
BHT-101	M{L2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnKXllKSzVyPUG2MlI1OzlizszN	M1PhdXNCVkeHUh?=
M059J	NG\rTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrp[5ZKSzVyPUG2MlI5PCEQvF2=	NGDEZY9USU6JRWK=
D-283MED	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHXPZh6UUN3ME2xOk41OjB7IN88US=>	MWnTRW5ITVJ?
BEN	NXfMVHBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[2TWM2OD1zNj61NVU2KM7:TR?=	M1LYXnNCVkeHUh?=
LB373-MEL-D	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DUeWlEPTB;MU[uO\|I{OiEQvF2=	MmrLV2FPT0WU
MEL-HO	MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXGTWM2OD1zNj64PFU1KM7:TR?=	NHznRWpUSU6JRWK=
GI-ME-N	M3HwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrVTWM2OD1zNj65NFMzKM7:TR?=	MkDQV2FPT0WU
RKO	NV\QUFJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nKW2lEPTB;MUeuNFc1QCEQvF2=	M4D4SHNCVkeHUh?=
MZ2-MEL	M2\QO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rQRWlEPTB;MUeuNVM{KM7:TR?=	MXLTRW5ITVJ?
NCI-H1573	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTF5LkK4NlYh\|ryP	M2DqRXNCVkeHUh?=
NCI-H1581	MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTF5LkS0NVEh\|ryP	MXvTRW5ITVJ?
NCI-H747	MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXXdVg2UUN3ME2xO{42Ojl5IN88US=>	NHjibZBUSU6JRWK=
SW1783	M2rB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfXTnRKSzVyPUG3MlY1OTVizszN	MV7TRW5ITVJ?
Calu-6	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTF5Lk[3PFIh\|ryP	MWrTRW5ITVJ?
SF268	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTF5Lk[5Olkh\|ryP	MXXTRW5ITVJ?
ES8	NWDIVFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LPcmlEPTB;MUeuPFU6OyEQvF2=	NEfhV2dUSU6JRWK=
KM-H2	M3PY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTF5Lkm0NVEh\|ryP	M1nuNnNCVkeHUh?=
D-502MG	M2iyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTF5Lkm4NFgh\|ryP	MmjSV2FPT0WU
HLE	NWntRlhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rIdGlEPTB;MUiuN\|E1QCEQvF2=	MnLoV2FPT0WU
SW982	NVzjZm1jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTF6LkSwO\|Uh\|ryP	MVvTRW5ITVJ?
MDA-MB-361	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml64TWM2OD1zOD61OVg5KM7:TR?=	NHvtfYFUSU6JRWK=
NCI-H1563	NYCwcXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTF6LkexNlQh\|ryP	MUPTRW5ITVJ?
MFE-280	Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLjPYhKSzVyPUG4MlczQTNizszN	M2q1WXNCVkeHUh?=
U251	NEnnTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF6LkezOFch\|ryP	MULTRW5ITVJ?
KNS-42	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfG[mFKSzVyPUG4MlgxOTVizszN	NEXQW3RUSU6JRWK=
U-266	M2fh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTF6Lki2OFkh\|ryP	MmThV2FPT0WU
OVCAR-8	NYizW45DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XjPWlEPTB;MUiuPVI4PiEQvF2=	M1rveXNCVkeHUh?=
MFH-ino	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXriTI9OUUN3ME2xPE46PjZ7IN88US=>	NVnDS5VZW0GQR1XS
D-263MG	M1Hs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TjVGlEPTB;MUmuNFE4OiEQvF2=	MVXTRW5ITVJ?
NCI-H1437	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTF7LkC0Olch\|ryP	NWLvR5Y6W0GQR1XS
NCI-H1048	M3nYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPwc41pUUN3ME2xPU4zOzJ4IN88US=>	NWSyfIJpW0GQR1XS
NCI-H446	M4fOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHPTWM2OD1zOT6zOVg6KM7:TR?=	M1XidnNCVkeHUh?=
NCI-N87	NEHkcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\PTWM2OD1zOT61PVkzKM7:TR?=	NXPOV3RkW0GQR1XS
WM-115	M2nMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTF7Lk[3O\|Qh\|ryP	NV7WenFwW0GQR1XS
HuH-7	M3zRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmH6TWM2OD1zOT63OFIyKM7:TR?=	NEfzNXFUSU6JRWK=
NCI-H650	NWGzOpNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXZbFJVUUN3ME2xPU44PTB6IN88US=>	NYK0O\|E5W0GQR1XS
TYK-nu	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHpTWM2OD1zOT64N\|c5KM7:TR?=	NF\BS5VUSU6JRWK=
Becker	NEHSUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkn1TWM2OD1zOT64OVQ4KM7:TR?=	MnPvV2FPT0WU
BB49-HNC	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTF7LkmyJO69VQ>?	M{jmWHNCVkeHUh?=
HGC-27	NYHnNnZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfuUHpPUUN3ME2yNE4yOzl2IN88US=>	NHjkVGJUSU6JRWK=
SiHa	M3\Nfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzXTWM2OD1{MD6zO\|EzKM7:TR?=	NEPZVndUSU6JRWK=
LB2518-MEL	M2THeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTJyLkO3N\|kh\|ryP	M1LLN3NCVkeHUh?=
TE-5	NFXrXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrtZVFKSzVyPUKwMlc1QDJizszN	MkLhV2FPT0WU
IST-SL1	NYHOO2FqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHr0NpdKSzVyPUKwMlc5PzlizszN	MYLTRW5ITVJ?
A375	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHsbYRKSzVyPUKxMlA2PjdizszN	M2C5fnNCVkeHUh?=
MC116	M4WyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rXVGlEPTB;MkGuNFczOyEQvF2=	NGPGb5NUSU6JRWK=
GI-1	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknLTWM2OD1{MT6xO{DPxE1?	NYfw[lNlW0GQR1XS
HOP-62	NIDuNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJzLkK3PFQh\|ryP	NGi2Rm1USU6JRWK=
PA-1	NED3OZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWm5doVYUUN3ME2yNU4zPzh5IN88US=>	NX7LNZd1W0GQR1XS
HT	M{jPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrhTWM2OD1{MT60N\|MyKM7:TR?=	NWLjWFdpW0GQR1XS
HUTU-80	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUL6NHMyUUN3ME2yNU41OzN4IN88US=>	NELCXmlUSU6JRWK=
NCI-H1975	M{fF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrDRVNKSzVyPUKxMlQ3OSEQvF2=	NIH0fXdUSU6JRWK=
GAK	M2GzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH6OIZKSzVyPUKxMlQ6QSEQvF2=	NI\6b3JUSU6JRWK=
SK-N-AS	Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rEfmlEPTB;MkGuOVYyQSEQvF2=	MUPTRW5ITVJ?
OE33	M3nEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHftWJRKSzVyPUKxMlYxPDZizszN	NUL3eFJFW0GQR1XS
YKG-1	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHtTWM2OD1{MT62OVQ2KM7:TR?=	NI\sVWFUSU6JRWK=
CAL-85	NGHh[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\TWWxMUUN3ME2yNU46OzB3IN88US=>	M2TubXNCVkeHUh?=
NCI-H2347	MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHYd4VKSzVyPUKxMlk1OjhizszN	M3\BVHNCVkeHUh?=
PANC-08-13	NELGcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPCTWM2OD1{Mj6wNVE6KM7:TR?=	MXLTRW5ITVJ?
SK-N-FI	NV3XSmY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7aOlE4UUN3ME2yNk4{ODd2IN88US=>	NX\wfXRjW0GQR1XS
NEC8	M2rp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jWdmlEPTB;MkKuOVA4QCEQvF2=	MWTTRW5ITVJ?
AN3-CA	NEnqXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn:wTWM2OD1{Mj62NFg1KM7:TR?=	NEfpVIdUSU6JRWK=
HuO9	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfuTWM2OD1{Mj63N\|k3KM7:TR?=	MlXyV2FPT0WU
COLO-800	M{\NNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPxTJhUUUN3ME2yNk44PjV\|IN88US=>	NGnmZ45USU6JRWK=
HT-29	M3\lTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTJ{Lki4NlMh\|ryP	M1G4[HNCVkeHUh?=
OC-314	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTJ{Lki4OFUh\|ryP	M4PLbXNCVkeHUh?=
G-401	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfVTWM2OD1{Mz6wOFYzKM7:TR?=	M4SyTHNCVkeHUh?=
Saos-2	NXK0XHpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJ\|LkWxPFIh\|ryP	MUDTRW5ITVJ?
UACC-62	NVL0ZldyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\oelNmUUN3ME2yN{42QDN\|IN88US=>	NH\Y[GFUSU6JRWK=
D-247MG	M3f0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vrRmlEPTB;MkOuO\|k{QSEQvF2=	M3HkWnNCVkeHUh?=
COLO-741	M364eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkeyTWM2OD1{Mz65OVY2KM7:TR?=	NXfFe\|JSW0GQR1XS
ES3	NIDpWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjuTWM2OD1{ND6wNFI{KM7:TR?=	MVnTRW5ITVJ?
LNCaP-Clone-FGC	NVvVfW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LzemlEPTB;MkSuNFIyOSEQvF2=	NWHJPGpOW0GQR1XS
SW1710	M4HUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTJ2LkG1NFYh\|ryP	NUPV[FJKW0GQR1XS
LU-99A	NIrKRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\STGlEPTB;MkSuNVg1OSEQvF2=	Mmi1V2FPT0WU
HOP-92	M3Lu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;qTWM2OD1{ND63NlUh\|ryP	M4S1UnNCVkeHUh?=
LS-123	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrETWM2OD1{ND65OlE1KM7:TR?=	NETsfHZUSU6JRWK=
T84	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF20UoxKSzVyPUK0Mlk4PjVizszN	NFfXUphUSU6JRWK=
HCT-116	NGD5b4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTFWHVvUUN3ME2yOU41OTh4IN88US=>	M3;p[HNCVkeHUh?=
M14	M2Lndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2f4ZmlEPTB;MkWuOFQ1PyEQvF2=	MW\TRW5ITVJ?
OCUB-M	MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHCTWM2OD1{NT60OFU3KM7:TR?=	M3y5cXNCVkeHUh?=
MKN45	Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTJ3Lk[zNVUh\|ryP	NVuwR4IyW0GQR1XS
LCLC-97TM1	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mon1TWM2OD1{NT63Nlg2KM7:TR?=	MYXTRW5ITVJ?
RVH-421	M4XVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnn4TWM2OD1{NT64NVYyKM7:TR?=	MmfnV2FPT0WU
NKS-81-FD	M37OO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPnRmxKSzVyPUK1MlkxOjFizszN	MmPPV2FPT0WU
NCI-H596	Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJ4LkC0PFch\|ryP	MnfkV2FPT0WU
GB-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTJ4LkG4O\|kh\|ryP	NVHBOox2W0GQR1XS
ZR-75-30	NY\N[pl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTJ4LkKyPVch\|ryP	NFe5WFRUSU6JRWK=
U-2-OS	NXHxWlJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TDfmlEPTB;Mk[uN\|c2PyEQvF2=	M1jrOXNCVkeHUh?=
HuP-T3	NHH6VXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjHTnFKSzVyPUK2MlYyODJizszN	NYLzO21oW0GQR1XS
MOLT-16	NUH3XmhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTJ4Lk[xOlYh\|ryP	NXnIPWRYW0GQR1XS
U-87-MG	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTJ4Lke0N\|gh\|ryP	MVXTRW5ITVJ?
8505C	NFzVWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\4eIhlUUN3ME2yOk46OTJ4IN88US=>	NVm4cndzW0GQR1XS
SK-MEL-3	NYO4WY5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\zTWM2OD1{Nj65PFI5KM7:TR?=	NHXWU5NUSU6JRWK=
COLO-824	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjsRXpKSzVyPUK3MlIyQTVizszN	NWDHNIJ5W0GQR1XS
EW-1	NXzk[ot2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXlfnNKSzVyPUK3MlM2PTRizszN	NVPjU\|VqW0GQR1XS
UACC-257	M1q4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonFTWM2OD1{Nz6zPFA1KM7:TR?=	MWnTRW5ITVJ?
Hs-578-T	NIfGTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJ5LkWyPVkh\|ryP	MmKxV2FPT0WU
UACC-893	M1fxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTJ5Lk[2N\|Eh\|ryP	M3m3bXNCVkeHUh?=
MHH-NB-11	NV3DOW05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDS[ndKSzVyPUK3MlgxODdizszN	NHXBdIVUSU6JRWK=
KYSE-410	NITKOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJ6LkK3O\|kh\|ryP	M3fjXnNCVkeHUh?=
SF126	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfwb29KSzVyPUK4Mlc1OzVizszN	M3O0eXNCVkeHUh?=
HT-144	NH3q[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PPVGlEPTB;MkmuN\|M3OiEQvF2=	M4jpPXNCVkeHUh?=
SW1573	NX20cFBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nv[WlEPTB;MkmuN\|UxQSEQvF2=	MUPTRW5ITVJ?
SW620	NETNTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVm5VXNWUUN3ME2yPU4{PjRzIN88US=>	M1LMRXNCVkeHUh?=
SCH	NFrBTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHEWoZKSzVyPUK5Mlg5OzFizszN	M3HsOXNCVkeHUh?=
EW-22	M{TyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPCbIVKSzVyPUOwMlE6PjlizszN	NGPUfXBUSU6JRWK=
H4	NYP3VXpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;ITWM2OD1\|MD60OlU1KM7:TR?=	NFfUeFZUSU6JRWK=
CAS-1	MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DDeWlEPTB;M{CuO\|g2QSEQvF2=	NVezXYdzW0GQR1XS
MG-63	NF7uVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PXdGlEPTB;M{CuPFQ4QCEQvF2=	NVy1PGZPW0GQR1XS
MDA-MB-415	Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zZfWlEPTB;M{GuNVc2OyEQvF2=	MnjFV2FPT0WU
NCI-H1395	MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2juRmlEPTB;M{GuNlMzQCEQvF2=	NFL1b5ZUSU6JRWK=
Ca-Ski	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTNzLkOxO\|ch\|ryP	MmPVV2FPT0WU
BxPC-3	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LFfWlEPTB;M{GuN\|czQSEQvF2=	NHzTToRUSU6JRWK=
A3-KAW	NFP0R2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjmbplKSzVyPUOxMlQ1PzFizszN	MWnTRW5ITVJ?
T-24	M3PrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzHPFhKUUN3ME2zNU44OzZ{IN88US=>	NYm5fo54W0GQR1XS
NCI-H2029	NEjYUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HUR2lEPTB;M{GuO\|c3PSEQvF2=	MWHTRW5ITVJ?
YAPC	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLpeJZYUUN3ME2zNk4xPDB5IN88US=>	MVXTRW5ITVJ?
SK-MEL-2	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrtbZhKSzVyPUOyMlA2OiEQvF2=	MlS3V2FPT0WU
LS-513	NULmTohDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTlNYNPUUN3ME2zNk4yOTh5IN88US=>	MknsV2FPT0WU
AsPC-1	NX7lWWF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PxV2lEPTB;M{KuN\|YxPSEQvF2=	M4HlTXNCVkeHUh?=
KYSE-150	M1mweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DXVmlEPTB;M{KuN\|c4OyEQvF2=	MVTTRW5ITVJ?
NCI-H520	NGXhNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2m3U2lEPTB;M{KuOFQ5OiEQvF2=	M2fzR3NCVkeHUh?=
JEG-3	NWfSUG5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmX2TWM2OD1\|Mz6wPVcyKM7:TR?=	NF3KS5dUSU6JRWK=
GMS-10	M3L5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnSOJVKSzVyPUOzMlMxODRizszN	NGPQZoRUSU6JRWK=
HT-1080	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:4[JBKSzVyPUOzMlM6KM7:TR?=	M3PNe3NCVkeHUh?=
NCI-H1651	NU\TeJprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4r0RWlEPTB;M{OuN\|k3KM7:TR?=	MWLTRW5ITVJ?
NCI-H2122	NY\PUlZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mom2TWM2OD1\|Mz61OVc1KM7:TR?=	MWnTRW5ITVJ?
ES5	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLzTWM2OD1\|Mz63NlkzKM7:TR?=	M3H1cXNCVkeHUh?=
8305C	MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTN\|Lkm5N\|ch\|ryP	MVTTRW5ITVJ?
KM12	NWHsU\|NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmi0TWM2OD1\|ND6wOFc5KM7:TR?=	M1PRRXNCVkeHUh?=
HCT-15	NEPxOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmX2TWM2OD1\|ND6xNlch\|ryP	NGHhNXFUSU6JRWK=
OVCAR-5	M4jqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTN2LkKxPFIh\|ryP	MUXTRW5ITVJ?
NCI-H2291	M3XMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrQcIFKSzVyPUO0MlI1PzJizszN	Mli4V2FPT0WU
CP50-MEL-B	NEPvNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmr2TWM2OD1\|ND62OVkzKM7:TR?=	M4\OZnNCVkeHUh?=
C-33-A	NFPROJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPmTWM2OD1\|ND62PFU4KM7:TR?=	M3y0WXNCVkeHUh?=
NCI-H2452	NUn2PGRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\uTWM2OD1\|ND63PFgzKM7:TR?=	M1vGPHNCVkeHUh?=
MDA-MB-157	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfZ[mdKSzVyPUO0MlgyQTNizszN	M4HX[3NCVkeHUh?=
LN-405	NWHtfldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTN3LkSzNFgh\|ryP	MUjTRW5ITVJ?
MDA-MB-231	M4TGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTN3LkWwOVQh\|ryP	Ml7hV2FPT0WU
EW-24	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfOSVlKSzVyPUO1MlY{OzVizszN	M2KzVXNCVkeHUh?=
MKN28	NH3CcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTN3LkiyN\|Yh\|ryP	MoW2V2FPT0WU
KINGS-1	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvSNo9KSzVyPUO1Mlg1OzRizszN	NHPzeW9USU6JRWK=
LC-2-ad	NVHPZZBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkf0TWM2OD1\|Nj62PVkh\|ryP	MWfTRW5ITVJ?
IGR-1	Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo[xTWM2OD1\|Nj63NFc2KM7:TR?=	NIjQZVFUSU6JRWK=
SW626	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvEPG5KSzVyPUO3MlA1OTdizszN	MVjTRW5ITVJ?
ONS-76	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWO2[4Y6UUN3ME2zO{4yOzB7IN88US=>	MV7TRW5ITVJ?
T98G	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TUTGlEPTB;M{euPFY{PSEQvF2=	NFv2VIJUSU6JRWK=
NB14	M1[ydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLDTWM2OD1\|OD60OVQ1KM7:TR?=	MWPTRW5ITVJ?
D-423MG	NUnwNplVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PSTmlEPTB;M{iuOFg3QSEQvF2=	NVHkOlAzW0GQR1XS
NCI-H510A	M2niPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HINmlEPTB;M{iuOlQ2OSEQvF2=	Ml;CV2FPT0WU
NMC-G1	NFHSc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvjUW57UUN3ME2zPE44OjJ{IN88US=>	NUftdGIxW0GQR1XS
SW948	NEnwW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTN6Lki5OFkh\|ryP	MVXTRW5ITVJ?
MFM-223	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHGwdlBKSzVyPUO4Mlk1OzFizszN	MmjtV2FPT0WU
PAN1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\vNGlEPTB;M{iuPVkyQSEQvF2=	M3jxdXNCVkeHUh?=
MZ7-mel	M4jBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH[2S5BKSzVyPUO5MlEyQTlizszN	MmL4V2FPT0WU
COLO-679	NXnCVVBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV[2NoR6UUN3ME2zPU46PzB6IN88US=>	MWfTRW5ITVJ?
SW872	NF;pSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlGyTWM2OD12MD6yNFMyKM7:TR?=	NIruVFlUSU6JRWK=
HT-1197	NFn3TldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTRyLkK4Olkh\|ryP	NHvIeXNUSU6JRWK=
ES6	NWPG[5lZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHBOlJZUUN3ME20NE41PTV{IN88US=>	NHHudINUSU6JRWK=
SNU-387	M2i0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEmydpZKSzVyPUSwMlgzOzhizszN	M120cnNCVkeHUh?=
T47D	NWT1UoNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rUNGlEPTB;NEGuNFE6OiEQvF2=	NHXrSIRUSU6JRWK=
G-402	NYnFW242T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPIWGRKSzVyPUSxMlA5ODlizszN	MnPVV2FPT0WU
MZ1-PC	NHjqb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nGXWlEPTB;NEGuPFEh\|ryP	MYPTRW5ITVJ?
SW1417	M4PHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\RUmZKSzVyPUSyMlMxOyEQvF2=	MVLTRW5ITVJ?
RERF-LC-MS	NUPLNnBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\wVWlEPTB;NEKuOVA5PyEQvF2=	NVPQfoxIW0GQR1XS
SF539	NWfk[5VoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHrc25CUUN3ME20Nk42PTJ7IN88US=>	MVTTRW5ITVJ?
ESS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTaT25kUUN3ME20N{42PTV6IN88US=>	NELwVolUSU6JRWK=
RO82-W-1	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDE[mxLUUN3ME20N{43OTV\|IN88US=>	M{TRbXNCVkeHUh?=
S-117	M1;yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTR\|Lk[5OVgh\|ryP	NX63NlhJW0GQR1XS
SW756	M{jtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnzZ5dmUUN3ME20N{45OjR{IN88US=>	MoCwV2FPT0WU
CP66-MEL	NILKUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37pc2lEPTB;NEWuO\|E1OyEQvF2=	NWf0emZ3W0GQR1XS
H-EMC-SS	NXzESYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXQO\|hLUUN3ME20OU44Pjl\|IN88US=>	NGfwSZFUSU6JRWK=
NCI-H2052	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3xTWM2OD12NT65NFI4KM7:TR?=	MVHTRW5ITVJ?
SW684	NVr4dFl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1i1PGlEPTB;NEeuNFA5OSEQvF2=	Mn3hV2FPT0WU
HCC1569	NW\1fpNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTR5LkG2OVgh\|ryP	NHX1S\|NUSU6JRWK=
KGN	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTR5LkOzNVEh\|ryP	M4PLPHNCVkeHUh?=
LCLC-103H	M2HpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfITWM2OD12Nz60OFA1KM7:TR?=	MlHXV2FPT0WU
SW780	NWq5e\|hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTR5Lk[zOVEh\|ryP	NWTC[Ih7W0GQR1XS
NCI-H1703	NYOwcJNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLQTWM2OD12OD6zN\|UzKM7:TR?=	M4XTUHNCVkeHUh?=
HCC1395	M1y3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVmzbZNlUUN3ME20PE44PDN{IN88US=>	M1TrOXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.
(Only for Reference)

Animal Research:^[3]

- Collapse

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Water	Insoluble
	Ethanol	''4 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292133	Recruiting	Drug: EGF816\|Drug: Gefitinib	Lung Cancer	Massachusetts General Hospital\|Novartis	October 31 2017	Phase 2
NCT03122717	Recruiting	Drug: Gefitinib\|Drug: Osimertinib	Non-Small Cell Lung Cancer	Dana-Farber Cancer Institute\|AstraZeneca	May 9 2017	Phase 1\|Phase 2
NCT02932345	Completed	--	EGFR Mutation Positive Advanced Non-small-cell Lung Cancer	AstraZeneca	October 31 2016	--
NCT02824458	Recruiting	Drug: Apatinib\|Drug: Gefitinib\|Drug: Placebo	EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors	Sun Yat-sen University	June 2016	Phase 3
NCT02804100	Unknown status	--	Carcinoma Non-Small-Cell Lung\|Bronchial Neoplasms\|Carcinoma Bronchogenic\|Lung Diseases\|Lung Neoplasms	Wenzhou Medical University	May 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)